Brassaiopsis glomerulata: A Comprehensive Reference
1. Identity and Botanical Classification
Taxonomy and Nomenclature
The species was first described as Aralia glomerulata by Carl Ludwig Blume in 1826 and later transferred to Brassaiopsis by Eduard August von Regel in 1863. Its accepted scientific name is therefore Brassaiopsis glomerulata (Blume) Regel. The species has accumulated several synonyms over time, reflecting taxonomic adjustments as more material was gathered; notable ones include Brassaiopsis speciosa Decne. & Planch., Macropanax glomerulatus (Blume) Miq., and Acanthopanax esquirolii H.Lév. Additional synonyms documented in the literature include Brassaiopsis acuminata H.L.Li and Brassaiopsis coriacea W.W.Sm.
Brassaiopsis glomerulata is a species of shrub in the family Araliaceae. The genus Brassaiopsis comprises about 46 species of shrubs and trees primarily distributed across eastern Asia, the Himalayas, and Indochina. The Araliaceae family is also home to other widely recognized medicinal plants, including ginseng (Panax spp.) and eleuthero (Eleutherococcus senticosus).
Morphology
Brassaiopsis glomerulata is a species of evergreen tree in the family Araliaceae, native to the subtropical and tropical regions of Southeast Asia, including the Eastern Himalayas and extending to southern China and western Java. It typically grows up to 20 meters tall in dense mountain forests, characterized by prickly branches, palmately compound leaves with 5–9 oblong to lanceolate leaflets, and terminal pendent inflorescences bearing clusters of small white flowers that develop into globose fruits.
More specifically, B. glomerulata is described as a large shrub or small tree with thorns on the stems, palmate leaves with 5–7 leaflets, pendulous panicles, and flowers in glomerulous heads (Regel, 1863).
Geographic Distribution
Brassaiopsis glomerulata is a member of the Araliaceae that occurs in south and southeast Asia, including the Vietnamese peninsula and in Indonesia. Following Blume's discovery in Java, B. glomerulata was documented from additional locales during 19th- and 20th-century botanical surveys, including collections in northeastern India by British explorers like David Prain and in southern China by Chinese and Western botanists such as H.L. Li. More broadly, the species is native across Nepal, the Eastern Himalayas, India (including Assam, Meghalaya, Arunachal Pradesh, Sikkim, Tripura, and Mizoram), Bangladesh, Bhutan, Myanmar, Thailand, Laos, Cambodia, Vietnam, southern China, the Malay Peninsula, Sumatra, and western Java in Indonesia.
Common Names
Regionally, the plant is known by various common names, including Drumstick Aralia in India (due to its elongated, stick-like leaf petioles), Tongcao in China (referring to its use as an "unblocking" herb), and Than mô or Ngô đồng in Vietnam; in Indonesia, it lacks a widely recorded vernacular but is recognized in Javanese herbal traditions.
Common Supplement Forms and Preparations
Brassaiopsis glomerulata is a species of shrub in the family Araliaceae; extracts are sold as bodybuilding supplements based on the assumption that aromatase inhibitors present in the plant might have effects in humans. In commerce, the plant material is most frequently encountered as a standardized leaf extract — often in ratios such as 10:1 — supplied in capsule or tablet form, and is frequently combined with other purported testosterone-supporting or estrogen-modulating botanical ingredients. Brassaiopsis supplements are frequently combined with other natural herbal supplements, such as curcumin, black pepper, and olive leaf.
2. Traditional and Historical Use
Vietnam
In Vietnam, the plant is used to treat rheumatism and back pain. In Vietnam, the leaves of B. glomerulata are traditionally used to treat rheumatism and back pain, often prepared as decoctions believed to exert anti-inflammatory effects. The plant has been specifically documented growing and used medicinally in the mountainous areas of northern Vietnam. Its leaves have been used as a traditional medicine in North Vietnam to treat rheumatism and back pain, as well as being used to treat gastritis, ulcers, and jaundice.
India — Naga Tribes
In India, a group of indigenous tribes called the Nagas drink a juice extract of B. glomerulata bark to aid in digestion and to alleviate constipation. The Nagas also used a paste of the bark of B. glomerulata to treat bone fractures and sprains (Changkija, 1999).
Ethnobotanical documentation from Arunachal Pradesh in India records additional uses by the Nyishi tribe: leaves of a plant identified in the literature as Brassiopsis glomerulata were used for diarrhoea, stomachache, and throat pain, while the fruit was used for cough, skin eruption, and abscesses.
China — Tongcao Classification
This species is also used medicinally in China as one of several kinds of "tongcao" (unblocking herbs used to promote urination and assist in lactation) (Shen et al., 1998). Several kinds of Xiaotongcao were reported to have obvious diuretic effects on rats; decoctions of different species of Tongcao and Xiao-tongcao were found to have anti-inflammatory, antipyretic, and diuretic effects, providing some pharmacological basis for their traditional clinical application.
Broader Southeast Asian Use
Ethnobotanical surveys and traditional medical texts from Vietnam and neighboring countries document the use of various Brassaiopsis species, including B. glomerulata, for anti-inflammatory purposes and to promote the healing of contusions. Brassaiopsis glomerulata is primarily used in traditional medicine, particularly in regions of Southeast Asia, where it is applied topically or used in poultices to help with the healing of bruises and minor injuries.
Traditional preparations have varied by region. Decoctions and infusions made from the plant are commonly consumed to alleviate pain, reduce fever, and help the body recover from fatigue and illness. It is important to note that ethnobotanical surveys and traditional medical texts from Vietnam and neighboring countries document these uses, but the rationale for its use is based on generational knowledge rather than rigorous clinical trials or pharmacological studies.
3. Phytochemistry: Key Constituents and Active Compounds
Lupane-Triterpenes (Leaves, Vietnam Collection)
The first reported phytochemical investigation of B. glomerulata leaves, carried out on Vietnamese plant material, yielded three known lupane-type triterpenes. These were: 3α-hydroxy-lup-20(29)-en-23,28-dioic acid (1), 3α-hydroxylup-20(29)-en-23,28-dioic acid 28-O-α-L-rhamnopyranosyl-(1→4)-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl ester (acankoreoside A, 2), and 3α,11α-dihydroxy-23-oxo-lup-20(29)-en-28-oic acid (3), isolated from the leaves of Brassaiopsis glomerulata (Blume) Regel, a species of Araliaceae family growing in Vietnam. Their structures were determined on the basis of spectroscopic data. The inclusion of acankoreoside A is notable because this compound and related lupane triterpenoids from the Araliaceae family have been implicated in NF-κB pathway modulation in other members of the family.
Aromatase-Inhibiting Compounds (Leaves, Indonesian Collection)
Very limited phytochemical studies have been performed on plants in the genus Brassaiopsis, with the only isolates reported to date being three known triterpenes of the lupane subgroup (Van Kiem et al., 2003). The pivotal 2009 study by Balunas et al. (University of Illinois at Chicago) substantially expanded knowledge of the plant's phytochemistry through bioassay-guided fractionation of Indonesian leaf material.
The hexane- and ethyl acetate-soluble extracts of the leaves of Brassaiopsis glomerulata (Blume) Regel (Araliaceae), collected in Indonesia, were found to inhibit aromatase, the rate-limiting enzyme in the production of estrogens from androgens, in both enzyme- and cell-based aromatase inhibition (AI) assays. Bioassay-guided fractionation led to the isolation of six known compounds of the steroid and triterpenoid classes (1–6) from the hexane extract, of which 6β-hydroxystimasta-4-en-3-one (5) was moderately active in the cell-based AI assay.
Fractionation of the ethyl acetate extract afforded seven pure isolates (7–13) of the modified peptide, fatty acid, monoterpenoid, and benzenoid types, including six known compounds and the new natural product, N-benzoyl-L-phenylalanine methyl ester (9). The absolute stereochemistry of 9 and the other two peptides, 7 and 8, was determined by Marfey's analysis.
In terms of biological activity from these 13 isolated compounds: Linoleic acid (10) was found to be active in the enzyme-based AI assay, while N-benzoyl-L-phenylalanine methyl ester (9) and (−)-dehydrololiolide (12) showed activity in the cell-based AI assay.
Particular attention has been drawn to (−)-dehydrololiolide: among the compounds showing aromatase inhibition properties, (−)-dehydrololiolide was found to be as effective as letrozole, an FDA-approved non-steroidal aromatase inhibitor. This comparison was made in vitro (cell-based assay conditions).
The activity of N-benzoyl-L-phenylalanine methyl ester was characterized more precisely in a separate review: the peptide, N-benzoyl-l-phenylalanine methyl ester (compound 28), was found to have weak AI activity in SK-BR-3 cells (33.3 PCA at 50 μM; no IC50 reported).
Fatty Acid Interference Caveat
A critical methodological finding from the same research program concerns the role of fatty acids in aromatase screening: the research also highlighted the effect of fatty acids on the accuracy of noncellular screening assays in natural product drug discovery. Unsaturated fatty acids were found to strongly inhibit the assay, whereas saturated fatty acids showed no inhibitory activity. However, these unsaturated fatty acids did not exhibit any activity on SK-BR-3 breast cancer cells, which are high in aromatase but hormone-independent. The study advises that during early drug discovery stages, especially when screening plant seeds, it is crucial to identify and remove fatty acids from extracts that are active in noncellular bioassays before continuing with bioassay-guided fractionation. This finding indicates that the linoleic acid activity observed in the noncellular enzyme assay may be an artifact of the assay conditions rather than a true biological signal.
Summary of Compound Classes
- Lupane-triterpenes: 3α-hydroxy-lup-20(29)-en-23,28-dioic acid; acankoreoside A; 3α,11α-dihydroxy-23-oxo-lup-20(29)-en-28-oic acid
- Steroids: 6β-hydroxystimasta-4-en-3-one (moderately active aromatase inhibitor in cell-based assay)
- Monoterpenoid: (−)-dehydrololiolide (potent aromatase inhibitor in cell-based assay, comparable to letrozole in vitro)
- Modified peptide (new natural product): N-benzoyl-L-phenylalanine methyl ester (weak AI activity in SK-BR-3 cells)
- Fatty acid: Linoleic acid (active in enzyme-based assay, but activity not replicated in cell-based assay; assay interference suspected)
4. Mechanisms of Action
Aromatase Inhibition
Inhibition of aromatase has been shown to reduce estrogen production throughout the body to nearly undetectable levels, and aromatase inhibitors are being used clinically to retard the development and progression of hormone-responsive breast cancers. FDA-approved aromatase inhibitors include anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®). The proposed mechanism by which B. glomerulata extract might modulate hormone balance is via inhibition of this same enzyme.
Substances from the leaves of Brassaiopsis glomerulata, found in Indonesia, have been found to inhibit the enzyme aromatase. Aromatase is responsible for converting androgens into estrogens. The study used enzyme- and cell-based assays to determine this inhibition.
The cell-based assay employed was particularly well-validated: samples found to be active using the noncellular assay were further tested at various concentrations in SK-BR-3 human breast cancer cells that overexpress aromatase, using a previously described method. Cells were treated in triplicate with samples or 0.1% DMSO (negative control) or 10 nM letrozole (positive control).
It is critical to note that all aromatase-inhibiting activity reported for B. glomerulata was demonstrated only in laboratory (in vitro) conditions. There is no evidence that Brassaiopsis glomerulata inhibits aromatase in vivo. No animal studies or human pharmacokinetic studies have been published to establish whether the bioactive compounds survive digestion, achieve relevant plasma concentrations, or reach target tissues at inhibitory levels.
Potential Anti-Inflammatory Mechanisms
The lupane-type triterpenes isolated from Vietnamese leaf material belong to a structural class known to possess anti-inflammatory properties in related Araliaceae species, potentially through modulation of NF-κB signaling and inhibition of pro-inflammatory cytokine release, as has been demonstrated for structurally related lupane triterpenoids in other plants. However, such mechanisms have not been directly demonstrated for B. glomerulata isolates in published studies; this mechanistic overlap is inferred from the compound class rather than from direct experimental evidence in this species.
5. Scientific Evidence by Area of Use
5.1 Aromatase Inhibition / Estrogen Modulation
Evidence level: In vitro only — no animal or human data.
The sole published peer-reviewed study directly examining B. glomerulata for aromatase inhibition is the 2009 Phytochemistry Letters paper by Balunas et al. (University of Illinois at Chicago). The hexane- and ethyl acetate-soluble extracts of the leaves of Brassaiopsis glomerulata, collected in Indonesia, were found to inhibit aromatase in both enzyme- and cell-based assays. Bioassay-guided fractionation led to the isolation of six known compounds of the steroid and triterpenoid classes from the hexane extract, of which 6β-hydroxystimasta-4-en-3-one was moderately active in the cell-based AI assay. Fractionation of the ethyl acetate extract afforded seven pure isolates of the modified peptide, fatty acid, monoterpenoid, and benzenoid types, including six known compounds and the new natural product, N-benzoyl-L-phenylalanine methyl ester.
The study used validated human breast cancer cell lines (SK-BR-3) that overexpress aromatase and compared findings against pharmaceutical aromatase inhibitors as controls. The comparison between (−)-dehydrololiolide and letrozole in terms of potency was made at specific in vitro concentrations in this cell-based system, and does not imply clinical equivalence.
Further investigations of Brassaiopsis glomerulata are needed on the mechanism of aromatase inhibition and in vivo testing. There is no evidence that Brassaiopsis glomerulata inhibits aromatase in vivo.
The effect of Brassaiopsis glomerulata on animals has not been investigated to any significant capacity. Clinical research on Brassaiopsis glomerulata has yet to be conducted.
5.2 Testosterone Support / Male Hormonal Health
Evidence level: Entirely speculative — no in vivo, animal, or human data.
The commercial use of B. glomerulata extracts as testosterone-boosting supplements follows logically from the in vitro aromatase inhibition finding: if aromatase conversion of testosterone to estrogen were reduced in vivo, circulating testosterone might theoretically increase. However, this chain of inference has never been tested in any living system. There is currently no existing research or data illustrating the effects of Brassaiopsis on living systems — human or animal. The supplement industry's use of B. glomerulata in testosterone-booster formulations is based entirely on extrapolation from in vitro phytochemistry.
5.3 Musculoskeletal Health (Rheumatism, Back Pain, Fractures)
Evidence level: Traditional use only — no clinical or preclinical pharmacological studies directly on B. glomerulata.
The use of this plant for rheumatism and back pain is well-documented ethnobotanically across multiple independent traditions, which lends the traditional claim some cultural weight. The rationale for its use is based on generational knowledge rather than rigorous clinical trials or pharmacological studies. While there are some laboratory studies on related Brassaiopsis species that demonstrate mild anti-inflammatory or analgesic activity, there is limited direct scientific investigation of B. glomerulata itself, especially in the context of bruise healing. Thus, the evidence is moderate, reflecting the presence of a longstanding traditional use but a lack of robust scientific validation.
5.4 Digestive Uses (Constipation, Gastritis)
Evidence level: Traditional use only — no clinical or preclinical data.
In India, a group of indigenous tribes called the Nagas drink a juice extract of B. glomerulata bark to aid in digestion and to alleviate constipation. Uses for gastritis and jaundice have been reported from Vietnam. No pharmacological or clinical studies have evaluated these uses.
5.5 Diuretic and Lactation Support (Traditional Chinese Medicine)
Evidence level: Traditional use with some indirect pharmacological support from related species — no direct human data for B. glomerulata.
This species is also used medicinally in China as one of several kinds of "tongcao" (unblocking herbs used to promote urination and assist in lactation) (Shen et al., 1998). Research on the broader "tongcao/xiaotongcao" category of Araliaceae herbs found that several kinds of Xiaotongcao had obvious diuretic effects on rats; decoctions of different species of Tongcao and Xiao-tongcao all have anti-inflammatory, antipyretic, and diuretic effects. This suggests a pharmacological basis for the traditional category, but direct evidence for B. glomerulata specifically is lacking.
5.6 Oncology / Chemopreventive Research
Evidence level: Preliminary in vitro — part of a broader natural product chemopreventive screening program.
As part of a research project directed toward the study of new naturally occurring chemopreventive agents from plants, the leaves of Brassaiopsis glomerulata (Blume) Regel (Araliaceae), collected in Indonesia, were found to inhibit the aromatase enzyme. The cell-based testing of aromatase inhibition was performed in SK-BR-3 human breast cancer cells. The plant was screened as a potential source of natural chemopreventive agents, but no anti-cancer activity was investigated or claimed beyond aromatase inhibition in these cell lines. No animal tumor models or clinical cancer studies have been conducted.
6. Body Systems and Health Areas Associated with Brassaiopsis glomerulata
- Endocrine / Hormonal system: Aromatase inhibition (estrogen biosynthesis modulation) demonstrated in vitro; testosterone-boosting effects speculative.
- Musculoskeletal system: Traditional use for rheumatism, back pain, bone fractures, and sprains; no controlled pharmacological evidence.
- Gastrointestinal system: Traditional use for constipation, gastritis, and digestive complaints; no pharmacological evidence.
- Urinary system: Traditional Chinese classification as a diuretic ("tongcao"); indirect support from studies on related species.
- Reproductive / Lactation support: Traditional Chinese use to assist lactation; no clinical evidence.
- Integumentary system: Traditional topical use for bruises, sprains, and wounds; no pharmacological evidence for this species specifically.
7. Dosage Forms and Dosages Reported in Available Sources
No human clinical studies have been conducted on B. glomerulata, and therefore no clinically validated dosage has been established. Clinical research on Brassaiopsis glomerulata has yet to be conducted. Typical supplements range from 200–500 mg of Brassaiopsis, which is often combined with other testosterone-boosting herbs.
Commercial preparations include:
- Loose leaf extract powder standardized for specific compounds (e.g., (−)-dehydrololiolide), dried and ground.
- Encapsulated leaf extracts at various extraction ratios (e.g., 10:1 concentration).
- Combination formulas in capsule or tablet form, where the Brassaiopsis component is one of several herbal ingredients.
The 200–500 mg daily range cited above reflects marketplace norms rather than any published dose-finding or dose-response research. No published studies report minimum effective doses, maximum tolerated doses, or pharmacokinetically relevant dosing intervals for any extract or isolated compound from B. glomerulata in humans or animals.
8. Safety Considerations and Potential Interactions
Overall Safety Data Gap
The effectiveness of Brassaiopsis glomerulata in treating various conditions is still under investigation. While some preliminary studies and anecdotal evidence suggest possible benefits, comprehensive clinical trials are lacking to provide conclusive evidence on its efficacy. Formal toxicology studies — acute toxicity, subchronic or chronic toxicity, reproductive toxicity, or genotoxicity — have not been published for B. glomerulata extracts or its isolated constituents at supplement-relevant doses.
Risks Inherent to Aromatase Inhibition as a Pharmacological Class
Although the aromatase-inhibiting effects of B. glomerulata have been demonstrated only in vitro, the class effect of aromatase inhibitors is well-characterized from pharmaceutical use. Some muscle-building products contained aromatase inhibitors. Use of aromatase inhibitors can lead to decreased bone maturation and growth, infertility, aggressive behavior, kidney failure, and liver dysfunction. These products pose a danger to consumers, especially young people and athletes who are often the target market for muscle-building products. These class-level risks from pharmaceutical-strength aromatase inhibitors are not confirmed for botanical extracts, but they provide a theoretical framework for caution.
Supplement Market Context and Regulatory Considerations
Extracts are sold as bodybuilding supplements based on the assumption that aromatase inhibitors present in the plant might have effects in humans. The supplement market for natural aromatase inhibitors has drawn regulatory scrutiny. A total of 92 adulterated muscle-building supplements were reported; this included products that had aromatase inhibitors declared on the label. The vast majority of adulterated muscle-building products identified from 2007 through 2016 were concentrated in just two years (2009 and 2010). While these regulatory actions were not directed specifically at B. glomerulata, they reflect the general risk environment of this product category.
Potential Drug Interactions (Theoretical)
Given the lack of human pharmacokinetic data, formal drug interaction studies do not exist. However, theoretically relevant considerations include: potential additive effects with pharmaceutical aromatase inhibitors (anastrozole, letrozole, exemestane); potential interference with hormone replacement therapies or oral contraceptives due to the proposed estrogen-lowering mechanism; and the general caution applicable to estrogen-sensitive conditions (hormone receptor-positive cancers) when using compounds with proposed anti-estrogenic activity.
Populations Without Established Safety Data
No safety data exist for use during pregnancy or lactation, in pediatric populations, or in individuals with pre-existing hepatic or renal impairment. Traditional use of the bark for lactation support in China does not constitute evidence that isolated or concentrated extracts are safe for this purpose.
Araliaceae Allergy Cross-Reactivity
As a member of the Araliaceae family — the same family as ginseng and eleuthero — there is a theoretical possibility of cross-reactivity in individuals with known sensitivities to other Araliaceae plants, though no documented cases specific to B. glomerulata have been published.
9. Current Status of Research and Evidence Summary
The totality of peer-reviewed scientific literature on Brassaiopsis glomerulata consists of two published phytochemical studies: the 2003 Van Kiem et al. paper (lupane triterpenes from Vietnamese leaves) and the 2009 Balunas et al. paper (aromatase inhibitors from Indonesian leaves). Both are in vitro or purely chemical in nature. Well-controlled human clinical trials examining the efficacy and safety of Brassaiopsis glomerulata are currently limited. While some preliminary studies and anecdotal evidence suggest possible benefits, comprehensive clinical trials are lacking to provide conclusive evidence on its efficacy.
The in vitro finding that (−)-dehydrololiolide compares in potency with letrozole in aromatase cell assays is scientifically interesting and has justified its inclusion in chemopreventive natural product research programs. However, equating this finding with human aromatase-inhibiting or testosterone-elevating effects represents an unvalidated extrapolation across the in vitro-to-human gap. The plant's ethnobotanical record across Vietnam, India, and China provides historical plausibility for anti-inflammatory and gastrointestinal applications, but these too lack controlled pharmacological investigation specific to this species.
References
- Balunas MJ, Su B, Riswan S, Fong HHS, Brueggemeier RW, Pezzuto JM, Kinghorn AD. Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett. 2009;2:29–33. PMC2748821
- Balunas MJ et al. Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). PubMed PMID 20161072
- Balunas MJ et al. Isolation and characterization of aromatase inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochemistry Letters. ScienceDirect.
- Van Kiem P, Dat NT, Van Minh C, et al. Lupane-triterpenes from the leaves of Brassaiopsis glomerulata. Arch Pharm Res. 2003;26:594–596. Springer Nature.
- Natural Product Compounds with Aromatase Inhibitory Activity: An Update. PMC2965731.
- Brassaiopsis glomerulata — Wikipedia
- Brassaiopsis glomerulata — Grokipedia
- Brassaiopsis glomerulata for Testosterone — Supplements in Review
- Brassaiopsis glomerulata is a Powerful Aromatase Inhibitor (in vitro) — Nutrient Journal
- Brassaiopsis Glomerulata — NutraPedia / NutraHacker
- Lupane-triterpenes from the leaves of Brassaiopsis glomerulata — ResearchGate
- Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata — ResearchGate
- Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US FDA Warnings — PMC6324457
- Exploring the multifaceted therapeutic potentials of Brassaiopsis palmata through in-vitro and in-vivo approaches. eFood, 2024.
- A review of medicinal plants used in the traditional healthcare system of Nyishi tribe of Arunachal Pradesh, Eastern Himalaya, India — ResearchGate
Go back